Dr. Kelly

W. Kevin Kelly, DO

Contact Dr. Kelly

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials
  2. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
  3. Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies
  4. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  5. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  6. Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy
  7. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma
  8. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
  9. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
  10. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
  11. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  12. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  13. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity
  14. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)
  15. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
  16. Effect of docetaxel on safety and efficacy of radium-223
  17. Practical guide to the use of enzalutamide
  18. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
  19. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)
  20. Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray